Core Insights - CytomX Therapeutics (CTMX) is approaching a significant trial readout for CX-2051, an antibody-drug conjugate being evaluated for colorectal cancer [1] Group 1: Company Overview - CTMX was rated a buy in October, indicating positive sentiment towards the stock ahead of the trial results [1] Group 2: Industry Context - The focus is on trading around key events such as trial results and regulatory approvals, highlighting the volatility and potential investment opportunities in the biotech sector [1]

Core Viewpoint - argenx SE has announced the discontinuation of the Phase 3 UplighTED studies evaluating efgartigimod for moderate to severe thyroid eye disease (TED) based on an Independent Data Monitoring Committee's recommendation due to futility [1][2] Group 1: Study Discontinuation - The Phase 3 UplighTED studies were halted after an interim analysis indicated that the trials did not meet the desired outcomes [2][3] - The decision reflects a responsible evaluation of the study's future likelihood of success, emphasizing the company's commitment to disciplined resource management [3] Group 2: Study Design and Objectives - The UplighTED studies were randomized, double-masked, placebo-controlled trials designed to assess the efficacy, safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of efgartigimod in adults with active, moderate-to-severe TED [4] - The primary endpoint was the percentage of participants who were proptosis responders at week 24, with key secondary endpoints including changes in proptosis measurement and quality of life scores [4] Group 3: Background on Thyroid Eye Disease - Thyroid Eye Disease (TED) is an autoimmune condition associated with Graves' disease and characterized by symptoms such as proptosis, diplopia, and potential vision loss, significantly impacting patient quality of life [5] Group 4: About Efgartigimod - Efgartigimod is a human IgG1 antibody fragment that reduces circulating IgG autoantibodies and is the first approved FcRn blocker for various autoimmune diseases [6]

On December 8, Kevin Mahn of Hennion & Walsh appeared on CNBC’s ‘Closing Bell Overtime’ to discuss the potential for another bullish year, but with more volatility. Mahn noted the possibility of a hawkish cut from the Fed coming up on Wednesday, which he believes could bode well for the markets. He supported this with historical data and stated that since 1950, the Fed has cut interest rates on 23 different occasions when the S&P 500 was within 2% of its all-time high, as it is currently. In all 23 of those ...

Core Insights - Wave Life Sciences Ltd. (NASDAQ: WVE) experienced a significant surge in share price, nearly tripling week-on-week, driven by positive results from its obesity drug clinical trial [1][2]. Clinical Trial Results - The first phase of the clinical trial for WVE-007 showed promising results, with a 4.5% total fat loss, 9.4% visceral fat reduction, and a 3.2% increase in lean mass over three months [3]. - No serious adverse reactions were reported during the trial, which contributed to investor confidence in the drug's safety and tolerability [3]. Future Expectations - Wave Life Sciences plans to release results from the second round of the clinical trial, which will include six-month data for the 240 mg single-dose cohort and three-month follow-up data for the 400 mg single-dose cohort [4][5]. - The company aims to evaluate WVE-007 as both a monotherapy and an add-on therapy for patients with higher BMI and related co-morbidities in phase 2 of the trial [5].

We recently published 10 Stocks Delivering Explosive 18-190% Gains. Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the last week’s heavy gainers. Terns Pharmaceuticals soared by 53 percent in just the past five trading days of the week, primarily buoyed by encouraging results from its therapy candidate for chronic myeloid leukemia (CML). In an updated report earlier in the week, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) said that its therapy candidate TERN-701 recorded a 64 percent improvement in t ...

Core Viewpoint - The law firm Kessler Topaz Meltzer & Check, LLP is investigating potential violations of federal securities laws on behalf of investors in uniQure N.V. following significant stock price decline after FDA feedback on its gene therapy AMT-130 [1][2][3] Group 1: Company Developments - On November 3, 2025, uniQure announced that the FDA indicated the data for its investigational gene therapy AMT-130 for Huntington's disease was insufficient to support its Biologics License Application (BLA) [2] - uniQure believes the FDA no longer considers the Phase I/II study data adequate for BLA submission, leading to uncertainty regarding the timing of the BLA submission for AMT-130 [2] Group 2: Market Reaction - Following the FDA's announcement, uniQure's stock price plummeted over 50%, dropping from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [3]

Core Viewpoint - The lawsuit against MoonLake Immunotherapeutics alleges that the company and its executives made false statements about the clinical efficacy of their drug candidate, sonelokimab, leading to a significant stock price drop of nearly 90% following disappointing trial results [2][4]. Summary by Relevant Sections Lawsuit Allegations - The lawsuit claims that MoonLake misled investors by asserting that the unique Nanobody structure of sonelokimab would provide superior clinical outcomes compared to traditional monoclonal antibodies, specifically against the FDA-approved BIMZELX [3]. Stock Performance - Following the announcement of the VELA-2 trial results, which failed to meet its primary endpoint and demonstrated inferior efficacy, MoonLake's stock plummeted from $61.99 to $6.24, representing a 90% loss [4]. Investor Actions - Investors who purchased MoonLake stock between March 10, 2024, and September 29, 2025, and experienced significant losses are encouraged to contact Hagens Berman to explore legal options and the possibility of becoming the Lead Plaintiff [5].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Alvotech due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by a press release from Alvotech on November 2, 2025, which announced that the U.S. FDA issued a complete response letter (CRL) for Alvotech's Biologics License Application (BLA) for AVT05, indicating deficiencies that must be resolved before approval [3]. - Following the announcement of the CRL, Alvotech's stock price experienced a significant decline, falling 34% on November 3, 2025, and nearly 4% on November 4, 2025 [3]. Group 2: Class Action Information - Shareholders who purchased Alvotech securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees or costs due to a contingency fee arrangement [2]. - Interested investors can join the prospective class action by visiting the provided link or contacting the law firm directly for more information [2]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and consistently ranking among the top firms for securities class action settlements since 2013 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of MoonLake Immunotherapeutics during the specified class period of the upcoming lead plaintiff deadline on December 15, 2025 [1] Group 1: Class Action Details - Investors who bought MoonLake common stock between March 10, 2024, and September 29, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6] - A lead plaintiff must file a motion with the court by December 15, 2025, to represent other class members in the litigation [3] Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company and has consistently ranked highly in securities class action settlements [4] Group 3: Case Allegations - The complaint alleges that during the class period, defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Telix Pharmaceuticals Ltd. securities between February 21, 2025, and August 28, 2025, about the upcoming lead plaintiff deadline for a securities class action lawsuit [1] Group 1: Class Action Details - Investors who bought Telix securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 9, 2026 [3] - The lawsuit alleges that defendants made materially false and misleading statements regarding Telix's progress in prostate cancer therapeutic candidates and the quality of its supply chain [5] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions of dollars for investors [4] - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [4]